Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.56 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27860339 | 1.00 | C3AR1 (0.56) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL29886799 | 0.90 | C3AR1 (0.49) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL187696 | 0.87 | C3AR1 (0.45) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL29476474 | 0.87 | C3AR1 (0.45) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL2116832 | 0.87 | C3AR1 (0.45) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL5497852 | 0.86 | C3AR1 (0.55) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL5497855 | 0.86 | C3AR1 (0.55) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL2815688 | 0.86 | C3AR1 (0.44) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL4587702 | 0.86 | C3AR1 (0.44) | C3AR1SHMT1CTDSP1GNPATNOD1 | |
| SCHEMBL4186382 | 0.85 | C3AR1 (0.59) | C3AR1SHMT1CTDSP1GNPATNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025088200-A2 | ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-05-01 | — | — | WO | claimed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | claimed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103740-A1 | CEACAM5-ANTIGEN-TARGETING ANTIBODY, ANTIBODY-DRUG CONJUGATE THEREOF AND USE THEREOF | 信达生物医药科技(杭州)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4615990-A1 | GLYCOSYNTHASE VARIANTS FOR ANTIBODY-DRUG CONJUGATE ENGINEERING | OBI Pharma, Inc. (TW) | 2025-09-17 | — | — | EP | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2008075369-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264605-A1 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| US-7138488-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-21 | — | — | US | disclosed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | disclosed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | C3AR1 77/4885SHMT1 3435/4885CTDSP1 4641/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | C3AR1 2149/4885SHMT1 4007/4885CTDSP1 1839/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | C3AR1 204/4885SHMT1 1407/4885CTDSP1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.